BMS-986142(一种可逆性布鲁顿酪氨酸激酶抑制剂)治疗类风湿关节炎的评估:一项2期、随机、双盲、剂量范围、安慰剂对照、适应性设计研究
这项2期随机双盲安慰剂对照适应性设计研究在14个国家79个中心纳入248例对甲氨蝶呤应答不佳的中重度类风湿关节炎患者,比较BMS-986142(100mg、200mg、350mg)与安慰剂每日一次口服12周的疗效与安全性。结果显示ACR20和ACR70主要终点均未达到,各剂量组与安慰剂无显著差异;350mg组因肝酶升高且无优于安慰剂的获益而提前终止。作者认为不宜进一步研究BMS-986142用于类风湿关节炎。
要点
- BMS-986142 100mg和200mg组ACR20、ACR70应答率与安慰剂无显著差异,主要终点未达到。
- 350mg组因肝酶升高且无优于安慰剂的获益,经预设期中分析后终止。
- 作者结论认为不宜在类风湿关节炎患者中进一步研究BMS-986142。
核心结论
- 作者认为不宜在类风湿关节炎患者中进一步研究BMS-986142。
- 本研究缺乏临床获益,结合其他研究结果,提示需进一步研究BTK抑制程度、治疗持续时间及药物向炎症部位分布是否充分,以理解BTK抑制作为类风湿关节炎治疗策略的潜在价值。
研究设计与样本
- 这是一项2期、随机、双盲、剂量范围、安慰剂对照、适应性设计研究,在14个国家的79个临床中心开展。
- 研究纳入年龄18岁及以上、筛查前至少16周确诊类风湿关节炎、对甲氨蝶呤应答不佳(伴或不伴对最多两种肿瘤坏死因子抑制剂应答不佳)的患者。
- 248例患者按1:1:1:1随机分配至口服BMS-986142 100mg、200mg、350mg或安慰剂每日一次,治疗12周;随机化使用交互式语音应答系统,按既往治疗状态和地理区域分层。
- 共同主要终点为第12周美国风湿病学会20%和70%改善标准(ACR20和ACR70)的应答率,在意向治疗疗效分析人群(所有随机化且至少接受一剂研究药物且未退出研究的患者)中评估。
- 安全性终点在as-treated分析人群(所有至少接受一剂研究药物的患者,按实际接受的治疗分组而非随机分配的治疗分组)中分析;试验注册号ClinicalTrials.gov NCT02638948。
主要发现
- 2016年2月24日至2018年5月3日期间,248例患者被随机分组(BMS-986142 100mg组73例、200mg组73例、350mg组26例、安慰剂组75例;随机化后排除1例);平均年龄56.7岁(SD 12.7);247例中女性214例(87%)、男性33例(13%),白人188例(76%)。
- 预设期中分析因肝酶升高且无优于安慰剂的获益,导致350mg BMS-986142剂量组终止。
- 共同主要终点未达到:ACR20应答率安慰剂组23/75(31%)、100mg组26/73(36%)、200mg组31/73(42%);ACR70应答率安慰剂组3/75(4%)、100mg组3/73(4%)、200mg组7/73(10%);与安慰剂相比均无显著差异。
- ACR20与安慰剂相比的差值估计:100mg组4.9(95%CI -10.2至20.1;p=0.52),200mg组11.8(95%CI -3.6至27.2;p=0.14);ACR70与安慰剂相比的差值估计:100mg组0.1(95%CI -16.0至16.5;名义p=1.00),200mg组5.6(95%CI -10.5至21.9;名义p=0.21)。
- 6例患者发生严重不良事件(安慰剂组4例:口腔溃疡、开放性眼球损伤、类风湿关节炎发作和子宫内膜腺癌;BMS-986142 100mg组2例:心绞痛和肠梗阻);无死亡。
关键数值与推荐
- 共同主要终点为第12周ACR20和ACR70应答率,在疗效分析人群中评估。
- ACR20应答率:安慰剂组31%(23/75)、100mg组36%(26/73)、200mg组42%(31/73);与安慰剂差值估计100mg组4.9(95%CI -10.2至20.1;p=0.52)、200mg组11.8(95%CI -3.6至27.2;p=0.14)。
- ACR70应答率:安慰剂组4%(3/75)、100mg组4%(3/73)、200mg组10%(7/73);与安慰剂差值估计100mg组0.1(95%CI -16.0至16.5;名义p=1.00)、200mg组5.6(95%CI -10.5至21.9;名义p=0.21)。
- 严重不良事件:安慰剂组4例(口腔溃疡、开放性眼球损伤、类风湿关节炎发作、子宫内膜腺癌),BMS-986142 100mg组2例(心绞痛、肠梗阻);无死亡。
临床怎么用
- 作者结论认为不宜在类风湿关节炎患者中进一步研究BMS-986142。
- 作者指出,本研究缺乏临床获益,结合其他研究结果,需进一步研究BTK抑制程度、治疗持续时间及药物向炎症部位分布是否充分,以理解BTK抑制作为类风湿关节炎治疗策略的潜在价值。
局限性
- 350mg BMS-986142剂量组因肝酶升高且无优于安慰剂的获益,经预设期中分析后终止,该组仅26例被随机分组。
- 作者结论认为不宜在类风湿关节炎患者中进一步研究BMS-986142,并指出需进一步研究BTK抑制程度、治疗持续时间及药物向炎症部位分布是否充分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bruton's tyrosine kinase (BTK) is a promising biological target for rheumatoid arthritis treatment. This study examined safety, efficacy, and pharmacokinetics of BMS-986142, an oral, reversible BTK inhibitor. The aim was to compare the efficacy of BMS-986142 with placebo on a background of methotrexate in patients with moderate-to-severe rheumatoid arthritis and inadequate response to methotrexate. METHODS: This phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study was conducted across 14 countries and 79 clinical sites. We recruited people aged 18 years or older with a documented diagnosis of rheumatoid arthritis at least 16 weeks before screening with an inadequate response to methotrexate with or without inadequate response to up to two tumour necrosis factor inhibitors. Participants were randomly assigned (1:1:1:1) to oral BMS-986142 (100 mg, 200 mg, or 350 mg) or placebo once daily for 12 weeks. Randomisation was done using an interactive voice response system and stratified by prior treatment status and geographical region. All participants, care providers, investigators, and outcome assessors were masked to treatment allocation. Co-primary endpoints were 20% and 70% improvement in American College of Rheumatology criteria (ACR20 and ACR70) at week 12. Primary endpoints were assessed in the efficacy analysis population (all randomised patients who received at least one dose of the study drug and did not discontinue the study). Safety endpoints were analysed in the as-treated analysis population, which included all patients who received at least one dose of the study drug (patients were grouped according to the treatment they actually received vs the treatment to which they were randomised). This trial was registered with ClinicalTrials.gov, number NCT02638948. FINDINGS: Between Feb 24, 2016 and May 3, 2018, 248 patients were randomised (73 in the BMS-986142 100 mg group, 73 in the 200 mg group, 26 in the 350 mg group, and 75 in the placebo group; one post-randomisation exclusion); mean age was 56·7 years (SD 12·7); 214 (87%) of 247 were women, 33 (13%) were men, and 188 (76%) were White. Pre-specified interim analysis resulted in discontinuation of the 350 mg BMS-986142 dose due to elevated liver enzymes and absence of benefit versus placebo. Co-primary endpoints were not met. Response rates for ACR20 (placebo: 23 [31%] of 75; 100 mg: 26 [36%] of 73; 200 mg: 31 [42%] of 73) and ACR70 (placebo: three [4%] of 75; 100 mg: three [4%] of 73; 200 mg: seven [10%] of 73) were not significantly different to placebo; estimate of difference versus placebo for ACR20 was 4·9 (95% CI -10·2 to 20·1; p=0·52) for 100 mg and 11·8 (-3·6 to 27·2; p=0·14) for 200 mg, and for ACR70 the estimate of difference was 0·1 (-16·0 to 16·5; nominal p=1·00) for 100 mg and 5·6 (-10·5 to 21·9; nominal p=0·21) for 200 mg. Six patients experienced serious adverse events (four in the placebo group [mouth ulceration, open globe injury, rheumatoid arthritis flare, and endometrial adenocarcinoma] and two in the BMS-986142 100 mg group [angina pectoris and intestinal obstruction]); there were no deaths. INTERPRETATION: Further investigation of BMS-986142 in people with rheumatoid arthritis is not warranted. An absence of clinical benefit in this study, together with other study results, highlights the need for additional research on the extent of BTK inhibition, treatment duration, and adequacy of drug distribution to inflammation sites, to understand the potential utility of BTK inhibition as a therapeutic strategy for rheumatoid arthritis. FUNDING: Bristol Myers Squibb.
引用
- Conaghan PG, Nowak M, Du S, et al. Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study. Lancet Rheumatol. 2023. PMID: 38251590. doi:10.1016/S2665-9913(23)00089-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。